On May 27, 2020 Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), reported that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transitioned to a new, virtual event format (Press release, TYME, MAY 27, 2020, View Source [SID1234558572]). The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cancer metabolism, pivotal trial in pancreatic cancer, clinical trial in ultra-rare metastatic sarcoma and expanding clinical plans for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, breast and/or hematological cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: BIO Digital
Place: View Source
Presentation Date: June 8-12, 2020

The presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com. There is no webcast for this event.